OPKO Health, Inc. (NASDAQ:OPK) CEO Purchases $780,000.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 500,000 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were acquired at an average price of $1.56 per share, with a total value of $780,000.00. Following the transaction, the chief executive officer now directly owns 212,411,477 shares in the company, valued at approximately $331,361,904.12. The trade was a 0.24 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, November 29th, Phillip Md Et Al Frost acquired 199,072 shares of OPKO Health stock. The shares were bought at an average cost of $1.53 per share, with a total value of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.59 per share, for a total transaction of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The shares were acquired at an average price of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Stock Performance

NASDAQ:OPK traded up $0.03 during mid-day trading on Wednesday, hitting $1.59. The stock had a trading volume of 2,995,388 shares, compared to its average volume of 6,819,181. OPKO Health, Inc. has a twelve month low of $0.85 and a twelve month high of $1.75. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -8.42 and a beta of 1.62. The company’s 50 day simple moving average is $1.53 and its 200 day simple moving average is $1.47.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on OPK shares. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a report on Thursday, September 26th. Piper Sandler reaffirmed an “overweight” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Tuesday, September 17th. Finally, Barrington Research reissued an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research report on Friday, November 8th.

Hedge Funds Weigh In On OPKO Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD raised its position in shares of OPKO Health by 4.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company’s stock valued at $536,000 after purchasing an additional 17,671 shares during the period. Comerica Bank boosted its holdings in shares of OPKO Health by 125.0% during the first quarter. Comerica Bank now owns 90,000 shares of the biotechnology company’s stock worth $108,000 after acquiring an additional 50,000 shares during the period. CIBC Asset Management Inc grew its position in shares of OPKO Health by 79.1% in the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 8,978 shares during the last quarter. PFG Investments LLC increased its stake in shares of OPKO Health by 2.5% during the second quarter. PFG Investments LLC now owns 960,965 shares of the biotechnology company’s stock worth $1,201,000 after purchasing an additional 23,700 shares during the period. Finally, American Century Companies Inc. acquired a new stake in OPKO Health during the 2nd quarter worth approximately $112,000. 64.63% of the stock is owned by institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.